Tumor vascular microenvironment determines responsiveness to photodynamic therapy

Cancer Research

Volumn 72, Issue 8, 2012, Pages 2079-2088

  Maas, Amanda L ^a   Carter, Shirron L ^a   Wiley, E Paul ^b   Miller, Joann ^a   Yuan, Min ^a   Yu, Guoqiang ^c,d   Durham, Amy C ^c   Busch, Theresa M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; MATRIGEL; PHOTOFRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RESPONSE; DRUG TUMOR LEVEL; DRUG UPTAKE; ISCHEMIA; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; BASEMENT MEMBRANE; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MICE; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PROTEOGLYCANS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860151945     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3744     Document Type: Article

References (50)

1. Maity A, Bernhard EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 2010;70:2141-5.
2. Casas A, Di Venosa G, Hasan T, Al B. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011;18:2486-515.
3. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011;71:6350-9.
4. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6. (Pubitemid 38697278)
5. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007;97:735-40. (Pubitemid 47396288)
6. Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, et al. Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res 2004;10:4630-8. (Pubitemid 38955512)
7. Zhou X, Chen B, Hoopes PJ, Hasan T, Pogue BW. Tumor vascular area correlates with photosensitizer uptake: analysis of verteporfin microvascular delivery in the Dunning rat prostate tumor. Photochem Photobiol 2006;82:1348-57. (Pubitemid 44702019)
8. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res 2006;12:5464-70. (Pubitemid 44497262)
9. Igbaseimokumo U. Quantification of in vivo Photofrin uptake by human pituitary adenoma tissue. J Neurosurg 2004;101:272-7. (Pubitemid 38971003)
10. Stylli SS, Howes M, MacGregor L, Rajendra P, Kaye AH. Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci 2004;11:584-96. (Pubitemid 38916966)
11. Huang Z, Chen Q, Shakil A, Chen H, Beckers J, Shapiro H, et al. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol 2003;78:496-502.
12. Zhou X, Pogue BW, Chen B, Demidenko E, Joshi R, Hoopes J, et al. Pretreatment photosensitizer dosimetry reduces variation in tumor response. Int J Radiat Oncol Biol Phys 2006;64:1211-20.
13. Busch TM, Xing X, Yu G, Yodh A, Wileyto EP, Wang HW, et al. Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy. Photochem Photobiol Sci 2009;8:1683-93.
14. Chen B, Pogue BW, Zhou X, O'Hara JA, Solban N, Demidenko E, et al. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005;11:720-7. (Pubitemid 40116900)
15. Zhou X, Pogue BW, Chen B, Hasan T. Analysis of effective molecular diffusion rates for verteporfin in subcutaneous versus orthotopic Dunning prostate tumors. Photochem Photobiol 2004;79:323-31.
16. Peng Q, Nesland JM. Effects of photodynamic therapy on tumor stroma. Ultrastruct Pathol 2004;28:333-40. (Pubitemid 39657538)
17. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005;15:378-86. (Pubitemid 41140305)
18. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF. A new mouse tumor model system (RIF-1) for comparison of endpoint studies. J Natl Cancer Inst 1980;64:595-604. (Pubitemid 10127278)
19. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-4. (Pubitemid 27043653)
20. Busch TM, Wileyto EP, Emanuele MJ, Del Piero F, Marconato L, Glatstein E, et al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res 2002;62:7273-9. (Pubitemid 36025249)
21. Busch TM, Hahn SM, Evans SM, Koch CJ. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3,-trifluoropropyl)acetamide]. Cancer Res 2000;60:2636-42. (Pubitemid 30318238)
22. Busch TM,Wang HW, Wileyto EP, Yu G, Bunte RM. Increasingdamage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate. Radiat Res 2010;174:331-40.
23. Bellnier DA, Greco WR, Parsons JC, Oseroff AR, Kuebler A, Dougherty TJ. An assay for the quantitation of Photofrin in tissues and fluids. Photochem Photobiol 1997;66:237-44. (Pubitemid 127470172)
24. Yu G, Durduran T, Zhou C, Wang HW, Putt ME, Saunders HM, et al. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin Cancer Res 2005;11:3543-52. (Pubitemid 40627910)
25. Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010;70:9277-86.
26. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.
27. Chen J, Lopez JA. Interactions of platelets with subendothelium and endothelium. Microcirculation 2005;12:235-46. (Pubitemid 40691821)
28. Fingar VH, Wieman TJ, Haydon PS. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem Photobiol 1997;66:513-7. (Pubitemid 127470199)
29. Dolmans DE, Kadambi A, Hill JS, Waters CA, Robinson BC, Walker JP, et al. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res 2002;62:2151-6. (Pubitemid 34408464)
30. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003;163:1801-15. (Pubitemid 37310012)
31. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009;100:865-9.
32. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27.
33. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood) 2007;232:1121-9. (Pubitemid 47503053)
34. Peng Q, Nesland JM, Moan J, Evensen JF, Kongshaug M, Rimington C. Localization of fluorescent Photofrin II and aluminum phthalocyanine tetrasulfonate in transplanted human malignant tumor LOX and normal tissues of nude mice using highly light-sensitive video intensification microscopy. Int J Cancer 1990;45:972-9. (Pubitemid 20179657)
35. Musser DA, Wagner JM, Datta-Gupta M. The interaction of tumor localizing porphyrins with collagen and elastin. Res Commun Chem Pathol Pharmacol 1982;36:251-9. (Pubitemid 12127393)
36. el-FarMA, Pimstone NR. The interaction of tumour-localizing porphyrins with collagen, elastin, gelatin, fibrin and fibrinogen. Cell Biochem Funct 1985;3:115-9.
37. Pazos MC, Nader HB. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz J Med Biol Res 2007;40:1025-35.
38. Vosko MR, Rother J, Friedl B, Bultemeier G, Kloss CU, Hamann GF. Microvascular damage following experimental sinus-vein thrombosis in rats. Acta Neuropathol 2003;106:501-5. (Pubitemid 37265855)
39. Fungaloi P, Statius van Eps R, Wu YP, Blankensteijn J, de Groot P, van Urk H, et al. Platelet adhesion to photodynamic therapy-treated extracellular matrix proteins. Photochem Photobiol 2002;75:412-7.
40. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther 2010;9:1798-808.
41. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 2006;12:3518-24.
42. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11. (Pubitemid 40127638)
43. Liu SY, Chang LC, Pan LF, Hung YJ, Lee CH, Shieh YS. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol 2008;44:277-85. (Pubitemid 351249195)
44. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63. (Pubitemid 40017699)
45. Jayne DG, Heath RM, Dewhurst O, Scott N, Guillou PJ. Extracellular matrix proteins and chemoradiotherapy: alpha5beta1 integrin as a predictive marker in rectal cancer. Eur J Surg Oncol 2002;28:30-6. (Pubitemid 41122779)
46. Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol 2010;36:636-47.
47. Eppley BL, Dadvand B. Injectable soft-tissue fillers: clinical overview. Plast Reconstr Surg 2006;118:98e-106e. (Pubitemid 44412913)
48. Kozin SV, Winkler F, Garkavtsev I, Hicklin DJ, Jain RK, Boucher Y. Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. Cancer Res 2007;67:5076-82. (Pubitemid 46997241)
49. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009;4:e6539.
50. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010;76:1537-45.